Identification of new prognostic biomarkers for stage III metastatic melanoma patients

Hojabr Kakavand; Richard A. Scolyer; John F. Thompson; Graham J. Mann

doi:10.4161/onci.25564

Identification of new prognostic biomarkers for stage III metastatic melanoma patients

Hojabr Kakavand
, Richard A. Scolyer
, John F. Thompson^*
, Graham J. Mann

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

Accurately predicting disease outcome among patients bearing Stage III metastatic melanoma is complex. However, current advances in personalized medicine call for ever more precise prognostic assessments, as these have a significant impact not only on the design and analysis of clinical trials, but also on therapeutic decision-making.

Original language	English
Article number	e25564
Journal	OncoImmunology
Volume	2
Issue number	9
DOIs	https://doi.org/10.4161/onci.25564
Publication status	Published - 2013
Externally published	Yes

Access to Document

10.4161/onci.25564

Cite this

@article{29e9240fa14843eeb1d63a91f400420d,

title = "Identification of new prognostic biomarkers for stage III metastatic melanoma patients",

abstract = "Accurately predicting disease outcome among patients bearing Stage III metastatic melanoma is complex. However, current advances in personalized medicine call for ever more precise prognostic assessments, as these have a significant impact not only on the design and analysis of clinical trials, but also on therapeutic decision-making.",

keywords = "BRAF, Expression profile, Melanoma, Metastasis, Mutation, NRAS, Outcome, Pathology, Prognosis, Treatment",

author = "Hojabr Kakavand and Scolyer, \{Richard A.\} and Thompson, \{John F.\} and Mann, \{Graham J.\}",

year = "2013",

doi = "10.4161/onci.25564",

language = "English",

volume = "2",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Taylor and Francis Ltd.",

number = "9",

}

TY - JOUR

T1 - Identification of new prognostic biomarkers for stage III metastatic melanoma patients

AU - Kakavand, Hojabr

AU - Scolyer, Richard A.

AU - Thompson, John F.

AU - Mann, Graham J.

PY - 2013

Y1 - 2013

N2 - Accurately predicting disease outcome among patients bearing Stage III metastatic melanoma is complex. However, current advances in personalized medicine call for ever more precise prognostic assessments, as these have a significant impact not only on the design and analysis of clinical trials, but also on therapeutic decision-making.

AB - Accurately predicting disease outcome among patients bearing Stage III metastatic melanoma is complex. However, current advances in personalized medicine call for ever more precise prognostic assessments, as these have a significant impact not only on the design and analysis of clinical trials, but also on therapeutic decision-making.

KW - BRAF

KW - Expression profile

KW - Melanoma

KW - Metastasis

KW - Mutation

KW - NRAS

KW - Outcome

KW - Pathology

KW - Prognosis

KW - Treatment

UR - https://www.scopus.com/pages/publications/84890280934

U2 - 10.4161/onci.25564

DO - 10.4161/onci.25564

M3 - Article

SN - 2162-4011

VL - 2

JO - OncoImmunology

JF - OncoImmunology

IS - 9

M1 - e25564

ER -

Identification of new prognostic biomarkers for stage III metastatic melanoma patients

Abstract

Access to Document

Other files and links

Fingerprint

Cite this